Sign in
4

Changes in Ownership

HALOZYME THERAPEUTICS, INC. Filed Acc 0001159036-26-000108

PRESIDENT AND CEO sold 60,000 shares at an average $104.59 ($6,275,592)

  • PRESIDENT AND CEO acquired 60,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Torley Helen · PRESIDENT AND CEO

Table I: Non-derivative

14 lines
Date Transaction Shares Price Value Owned after D/I
2026-08-17 Exercise or conversion : show line 1 in the form 10b5-1 +20,000 $18.41 $368,200 787,780 D
2026-08-17 Sale : show line 2 in the form 10b5-1 −900 $98.96 $89,062 786,880 D
2026-08-17 Sale : show line 3 in the form 10b5-1 −500 $100.46 $50,229 786,380 D
2026-08-17 Sale : show line 4 in the form 10b5-1 −2,100 $101.77 $213,709 784,280 D
2026-08-17 Sale : show line 5 in the form 10b5-1 −9,000 $102.55 $922,977 775,280 D
2026-08-17 Sale : show line 6 in the form 10b5-1 −7,500 $103.48 $776,115 767,780 D
2026-08-18 Exercise or conversion : show line 7 in the form 10b5-1 +20,000 $18.41 $368,200 787,780 D
2026-08-18 Sale : show line 8 in the form 10b5-1 −5,703 $103.08 $587,882 782,077 D
Open-market sales · 60,000 sh · avg $104.59 · $6,275,592

Table II: Derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2026-08-17 Exercise or conversion : show line 15 in the form 10b5-1 Option to Purchase Common Stock −20,000 $18.41 $368,200 181,552 D
2026-08-18 Exercise or conversion : show line 16 in the form 10b5-1 Option to Purchase Common Stock −20,000 $18.41 $368,200 161,552 D
2026-08-19 Exercise or conversion : show line 17 in the form 10b5-1 Option to Purchase Common Stock −20,000 $18.41 $368,200 141,552 D
Loading xslF345X06/wk-form4_1787184072.xml…